| 吴雨哲,胡少勃,程翔,等.动脉化疗栓塞联合阿帕替尼治疗原发性肝癌伴门静脉瘤栓 71例疗效分析[J].安徽医药,2021,25(6):1118-1120. |
| 动脉化疗栓塞联合阿帕替尼治疗原发性肝癌伴门静脉瘤栓 71例疗效分析 |
| Curative effect of transarterial chemoembolization combined Apatinib in primary liver carcinoma with portal vein tumor thrombus in 71 Cases |
| |
| DOI：10.3969/j.issn.1009-6469.2021.06.013 |
| 中文关键词: 肝肿瘤 化学栓塞，治疗性 门静脉瘤栓 阿帕替尼 疗效 |
| 英文关键词: Liver neoplasms Chemoembolization, therapeutic Portal vein tumor thrombus Apatinib Curative effect |
| 基金项目:国家自然科学基金资助项目( 81372668) |
|
| 摘要点击次数: 2072 |
| 全文下载次数: 685 |
| 中文摘要: |
| 目的探讨动脉化疗栓塞( TACE)联合阿帕替尼治疗原发性肝癌伴门静脉瘤栓疗效及安全性。方法选择 2016年 1月至 2017年 6月华中科技大学同济医学院附属协和医院诊治的 149例原发性肝癌伴门静脉瘤栓病人为研究对象，根据病人治疗方法分为 TACE联合阿帕替尼组( 71例)和单纯 TACE组( 78例)多因素 Cox风险比例模型、生存曲线及 log-rank检验用来比较两组疗效及总生存期的区别。结果多因素 Cox风险比例模型，证实联合阿帕替尼是肝癌预后的保护因素 HR(95%CI):0.415(0.236~0.735)P = 0.003，生存曲线及 log-rank检验证实 TACE联合阿帕替尼组中位生存期显著高于单纯 TACE组［(18.4±2.8)月比(13.6±1.2< 0.001］。 TACE联合阿帕替尼组高血压、手足皮肤反应、蛋白尿并发症发生率高于单纯 TACE组( P<)月，P，0.05)在消化道症状、骨髓抑制及肝功能损伤方面的差异无统计学意义( P<0.05)。结论阿帕替尼联合 TACE治疗原发性肝癌伴门静，脉瘤栓病人疗效显著优于单纯 TACE治疗，具有高效安全等优点。 |
| 英文摘要: |
| Objective To explore the curative effect and safety of transarterial chemoembolization (TACE) combined Apatinib intreating primary liver cancer (PLC) with portal vein tumor thrombus (PVTT).Methods From January 2016 to June 2017, 149 patientsof primary liver cancer combined with portal vein tumor thrombus, diagnosed and treated in Union Hospital of Tongji Medical College,Huazhong University of Science and Technology, were selected as the research objects. Patients were assigned into TACE combinedwith apatinib group (n=71) and TACE-alone group (n=78) according to the therapies. Multivariate Cox proportional hazards models, survival curve and log-rank test were used to compare the efficacies and the overall survival between the two groups.Results Multivariate Cox proportional hazards models verified that Apatinib was a protective factor for PLC with PVTT [HR(95%CI): 0.415(0.236-0.735), P= 0.003]. Survival curve and log-rank test verified that the median survival time of patients treated by TACE combined Apatinib was significantly longer than TACE-alone group [(18.4±2.8) months vs. (13.6±1.2) months, P < 0.001]. The incidence rates of hypertension, hand-foot-skin reaction, and proteinuria in the TACE combined with apatinib group were higher than those in the TACE-alone group (P <0.05), and there were no statistically significant differences in gastrointestinal symptoms, bone marrow suppression and liver damage(P<0.05).Conclusion Apatinib combined with TACE in the treatment of primary liver cancer combined with portal vein tumor thrombosis achieves better efficacy than TACE alone, which has the advantages of high efficiency and safety. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
